Literature DB >> 16254056

Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

A Faustini1, A J Hall, C A Perucci.   

Abstract

BACKGROUND: The resurgence of tuberculosis (TB) in western countries has been attributed to the HIV epidemic, immigration, and drug resistance. Multidrug resistant tuberculosis (MDR-TB) is caused by the transmission of multidrug resistant Mycobacterium tuberculosis strains in new cases, or by the selection of single drug resistant strains induced by previous treatment. The aim of this report is to determine risk factors for MDR-TB in Europe.
METHODS: A systematic review was conducted of published reports of risk factors associated with MDR-TB in Europe. Meta-analysis, meta-regression, and sub-grouping were used to pool risk estimates of MDR-TB and to analyse associations with age, sex, immigrant status, HIV status, occurrence year, study design, and area of Europe.
RESULTS: Twenty nine papers were eligible for the review from 123 identified in the search. The pooled risk of MDR-TB was 10.23 times higher in previously treated than in never treated cases, with wide heterogeneity between studies. Study design and geographical area were associated with MDR-TB risk estimates in previously treated patients; the risk estimates were higher in cohort studies carried out in western Europe (RR 12.63; 95% CI 8.20 to 19.45) than in eastern Europe (RR 8.53; 95% CI 6.57 to 11.06). National estimates were possible for six countries. MDR-TB cases were more likely to be foreign born (odds ratio (OR) 2.46; 95% CI 1.86 to 3.24), younger than 65 years (OR 2.53; 95% CI 1.74 to 4.83), male (OR 1.38; 95% CI 1.16 to 1.65), and HIV positive (OR 3.52; 95% CI 2.48 to 5.01).
CONCLUSIONS: Previous treatment was the strongest determinant of MDR-TB in Europe. Detailed study of the reasons for inadequate treatment could improve control strategies. The risk of MDR-TB in foreign born people needs to be re-evaluated, taking into account any previous treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16254056      PMCID: PMC2104570          DOI: 10.1136/thx.2005.045963

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  43 in total

1.  Classification of drug-resistant tuberculosis in an epidemic area.

Authors:  A Van Rie; R Warren; M Richardson; R P Gie; D A Enarson; N Beyers; P D Van Helden
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

2.  Surveillance of antituberculosis drug resistance in Switzerland 1995-1997: the central link.

Authors:  P Helbling; E Altpeter; P A Raeber; G E Pfyffer; J P Zellweger
Journal:  Eur Respir J       Date:  2000-08       Impact factor: 16.671

3.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  M A Espinal; A Laszlo; L Simonsen; F Boulahbal; S J Kim; A Reniero; S Hoffner; H L Rieder; N Binkin; C Dye; R Williams; M C Raviglione
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

4.  Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group.

Authors:  J Robert; D Trystram; C Truffot-Pernot; B Carbonnelle; J Grosset
Journal:  Int J Tuberc Lung Dis       Date:  2000-07       Impact factor: 2.373

5.  Primary and acquired drug resistance in Polish tuberculosis patients: results of a study of the national drug resistance surveillance programme.

Authors:  Z Zwolska; E Augustynowicz-Kopec; M Klatt
Journal:  Int J Tuberc Lung Dis       Date:  2000-09       Impact factor: 2.373

6.  [Resistance of Mycobacterium tuberculosis in Zaragoza, Spain (1993-1997) and related factors].

Authors:  L Torres; P Arazo; J Blas Pérez; M del Pilar Amador; M Antonia Lezcano; M José Revillo; J Bautista García-Moya
Journal:  Med Clin (Barc)       Date:  2000-11-11       Impact factor: 1.725

7.  Tuberculosis drug resistance in England and Wales. How much is 'home-grown'?

Authors:  A C Hayward; J Herbert; J M Watson
Journal:  Epidemiol Infect       Date:  2000-10       Impact factor: 2.451

8.  Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis.

Authors:  S Lockman; A Kruuner; N Binkin; K Levina; Y Wang; M Danilovitsh; S Hoffner; J Tappero
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

9.  Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993.

Authors:  T Schaberg; G Gloger; B Reichert; H Mauch; H Lode
Journal:  Eur Respir J       Date:  1995-02       Impact factor: 16.671

10.  Epidemiology and ethnic distribution of multidrug-resistant tuberculosis in southern Israel, 1992-1997: the impact of immigration.

Authors:  J Gilad; A Borer; K Riesenberg; N Peled; F Schlaeffer
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

View more
  137 in total

1.  Outcome of hospitalized MDR-TB patients: Israel 2000-2005.

Authors:  D Bendayan; A Hendler; V Polansky; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-23       Impact factor: 3.267

2.  A childhood case of spinal tuberculosis misdiagnosed as muscular dystrophy.

Authors:  Doo Il Song; Su Ye Sohn; Yun Kyung Kim; So Hee Eun; Young Jun Rhie; Gi Young Jang; Chan Wook Woo; Byung Min Choi; Jung Hwa Lee; Bo Kyung Je
Journal:  Korean J Pediatr       Date:  2010-05-31

Review 3.  Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge.

Authors:  Robert Loddenkemper; Barbara Hauer
Journal:  Dtsch Arztebl Int       Date:  2010-01-07       Impact factor: 5.594

4.  High prevalence of multidrug-resistant tuberculosis in Georgia.

Authors:  Nino Mdivani; Ekaterina Zangaladze; Natalia Volkova; Ekaterina Kourbatova; Thea Jibuti; Natalia Shubladze; Tamar Kutateladze; George Khechinashvili; Carlos del Rio; Archil Salakaia; Henry M Blumberg
Journal:  Int J Infect Dis       Date:  2008-06-02       Impact factor: 3.623

5.  Use of GeneXpert Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance tuberculosis cases.

Authors:  Kheira Guenaoui; Noria Harir; Aissa Ouardi; Soumia Zeggai; Feriel Sellam; Farid Bekri; Sakina Cherif Touil
Journal:  Ann Transl Med       Date:  2016-05

6.  Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia.

Authors:  Omar Salad Elmi; Habsah Hasan; Sarimah Abdullah; Mat Zuki Mat Jeab; Zilfalil Ba; Nyi Nyi Naing
Journal:  Malays J Med Sci       Date:  2016-06-30

7.  Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data.

Authors:  Michelle E Kruijshaar; John M Watson; Francis Drobniewski; Charlotte Anderson; Timothy J Brown; John G Magee; E Grace Smith; Alistair Story; Ibrahim Abubakar
Journal:  BMJ       Date:  2008-05-01

Review 8.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

9.  Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors.

Authors:  X Shen; K DeRiemer; Z-An Yuan; M Shen; Z Xia; X Gui; L Wang; Q Gao; J Mei
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

10.  Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey.

Authors:  Sahal Al-Hajoj; Bright Varghese; Mohammed M Shoukri; Ruba Al-Omari; Mais Al-Herbwai; Fahad Alrabiah; Abdulrahman A Alrajhi; Naila Abuljadayel; Sahar Al-Thawadi; Alimuddin Zumla; Matteo Zignol; Mario C Raviglione; Ziad Memish
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.